| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-023991.txt","as_of":"2026-04-08T02:28:02.401723+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-023991.txt","company":"TriSalus Life Sciences, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-023991.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_277168cb32c0a35c","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-023991.txt","content_type":"text/plain","enriched_at":"2026-04-08T03:37:35.557980+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"tlsi-20260401","final_url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-023991.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-023991.txt","source_event_id":"evt_47da7b5d0115","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"1b4fe628fcae6e70","kind":"sec_filing","published_at":"20260407","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-01","2026-04-07","2026-06-29"],"entities":[{"asset_class":"equity","name":"TriSalus Life Sciences, Inc.","relevance":"high","symbol":"TLSI","type":"issuer"},{"asset_class":"person","name":"Dr. Richard Marshall","relevance":"high","symbol":"","type":"individual"},{"asset_class":"person","name":"David Patience","relevance":"medium","symbol":"","type":"individual"}],"event_type":"other","information_gaps":["What changed vs prior known state is not provided in the signal beyond the fact that this 8-K was filed; no prior filing/previous CMO status is included in the provided text.","The specific content of the press release beyond the exhibit reference is truncated in the provided text (EX-99.1 begins but is cut off).","No details are provided about whether Dr. Marshall replaces a prior CMO or about termination/resignation of any prior officer (Item 5.02 is referenced but no prior officer changes are described in the provided excerpt)."],"key_facts":["Form 8-K filed by TriSalus Life Sciences, Inc. with date of report/earliest event reported as April 1, 2026.","On April 1, 2026, the Company entered into an offer letter with Dr. Richard Marshall for the position of Chief Medical Officer.","Dr. Marshall\u2019s employment is expected to start on June 29, 2026.","Dr. Marshall\u2019s annual base salary is $525,000 and he will receive a sign-on bonus of $250,000.","Dr. Marshall is eligible for an annual bonus of up to 50% of his annual base salary based on achievement of financial goals and milestones determined by the Board.","Following the start of employment, the Company will recommend an equity award to Dr. Marshall consisting of 120,000 stock options and 60,000 restricted stock units.","Dr. Marshall is eligible for an annual equity grant under the Company\u2019s Equity Incentive Plan, subject to Board approval.","The filing states there have been no related party transactions between Dr. Marshall and the Company required to be disclosed under Item 404(a) of Regulation S-K.","On April 7, 2026, the Company issued a press release announcing Dr. Marshall\u2019s appointment effective June 29, 2026.","Exhibit 99.1 is the press release dated April 7, 2026; Item 7.01 states the information is not deemed filed for Section 18 liabilities and not incorporated by reference except as expressly set forth."],"numeric_claims":[{"label":"Annual base salary (USD)","value":"525,000"},{"label":"Sign-on bonus (USD)","value":"250,000"},{"label":"Annual bonus maximum (% of base salary)","value":"50%"},{"label":"Stock options (number)","value":"120,000"},{"label":"Restricted stock units (number)","value":"60,000"},{"label":"Employment start date","value":"2026-06-29"},{"label":"Press release date","value":"2026-04-07"}],"primary_claim":"TriSalus Life Sciences entered into an offer letter on April 1, 2026 with Dr. Richard Marshall for the Chief Medical Officer position, with employment expected to start June 29, 2026, and issued a press release on April 7, 2026 (Exhibit 99.1).","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"TriSalus Life Sciences, Inc. filed a Form 8-K announcing the appointment of Dr. Richard Marshall as Chief Medical Officer, effective June 29, 2026. The filing discloses compensation terms and attaches a press release as Exhibit 99.1.","topics":["8-K filing","Chief Medical Officer appointment","offer letter","executive compensation","Regulation FD press release","Exhibit 99.1"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 TriSalus Life Sciences, Inc. \u00b7 Filed 20260407","ticker":"TLSIW","tickers":["TLSIW"],"title":"TLSIW filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1826667/0001628280-26-023991.txt"}... |